Keywords: Amgen, Xgeva, USA, FDA, Prostate cancer, Bone metastases

Amgen files Xgeva with FDA for additional indication

Article | 29 June 2011

Print This

US biotech major Amgen (Nasdaq: AMGN) has submitted a supplemental Biologics License Application (sBLA) to the Food and Drug Administration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in